Endovascular Aneurysm Stabilization Treatment

Nectero Medical is at the forefront of developing innovative therapies aimed at treating abdominal aortic aneurysms (AAAs), particularly focusing on small to mid-sized AAAs that currently lack effective treatment options. The company's flagship technology, the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, employs a minimally invasive endovascular approach. This system utilizes a dual-balloon delivery catheter to administer a proprietary stabilizer mixture containing pentagalloyl glucose (PGG) directly to the aneurysmal wall. PGG is designed to bind with elastin and collagen, potentially reinforcing the aortic vessel wall and mitigating the risk of aneurysm growth and rupture. The procedure is quick, taking less than an hour, and does not leave behind any permanent implants, allowing for future interventions if necessary.

The Nectero EAST® System is currently undergoing clinical trials, with the aim of providing a therapeutic option for patients with infrarenal AAAs measuring between 3.5 cm and 5.0 cm in diameter. The FDA has granted Investigational New Drug (IND) clearance for the initiation of a multi-center, randomized clinical trial to assess the safety and efficacy of this treatment. Additionally, the system received Breakthrough Therapy designation from the FDA, which is intended to expedite its development and review process due to its potential to significantly improve treatment outcomes for a serious medical condition. Early clinical data has shown promising results, indicating procedural success and safety, which supports the continued investigation of this novel approach to aneurysm management.

United States

Nectero Medical is a clinical-stage biotech company pioneering novel therapies with a potential to treat aneurysmal disease and improve patients' lives.

Nectero Medical

Company Details